I
n 2011, transcatheter aortic valve replacement (TAVR) was approved for commercial use in the United States for patients deemed at high risk for surgical aortic valve replacement. 1 Since that time, adoption of TAVR has expanded to commercial use for intermediate-risk patients and randomized trials for low-risk patients. Advancements in device design and delivery systems, as well as increased procedural experience, have led to similar rates of death or stroke for patients receiving TAVR and surgical aortic valve replacement. 2, 3 As a result, TAVR numbers in the United States have skyrocketed. The annual US TAVR volume in 2012 was 4627. In 2015, the annual volume rose to 24 808. 4 Incorporating low-risk patients into this mix will dramatically increase these volumes because low-risk patients comprise ≈80% of patients with aortic stenosis.
TAVR programs are multidisciplinary, and outcomes are influenced by providers from a number of disciplines, including cardiology, cardiac surgery, radiology, and anesthesiology. Although some consensus exists around the procedure's performance, no consensus has occurred on optimal anesthetic management. Of particular importance is the fundamental choice between general anesthesia (GA) and conscious sedation (CS) and its potential impact on outcome. This question is not limited to the population receiving TAVR but most recently has been hotly debated among experts in the TAVR field and covered extensively in TAVR literature.
In the early days of TAVR, GA was used for all cases. However, it was quickly realized that CS for TAVRs was feasible, with initial reports from Europe followed by several US case series. Recently, a multitude of small observational studies have examined the safety and efficacy of anesthetic choice and found that CS, when compared with GA for TAVRs, was associated with shorter hospital duration, shorter procedural times, fewer inotropes, and lower cost without compromising procedural success. 5, 6 However, many of these studies were limited by observational status, small sample sizes, study design, and narrow generalizability. Currently, no large population-based US studies have compared CS and GA for use in a broad clinical setting.
In this issue of Circulation, Hyman and colleagues 7 address this knowledge gap. They examined data from 10 997 patients undergoing percutaneous transfemoral TAVRs between April 2014 and June 2015, using the Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapy Registry. Anesthesia type was coded using a standard definition as general anesthesia (loss of consciousness without arousability) or conscious sedation (depression of consciousness with preservation of response to verbal commands). The primary outcome was inhospital mortality. To examine safety and efficacy, an array of secondary outcomes was examined. This study offers several results. First, the authors found that even during the short 15-month period of analysis, the frequency of CS increased sub-stantially. Second, in both unadjusted and propensity analyses, TAVR with CS was associated with reduced in-hospital and 30-day mortality. Third, the need for intraprocedural inotropes, intensive care unit length of stay, and hospital length of stay were reduced in the CS group. In adjusted models, intraprocedural success was high in both groups (>97%), although slightly but not significantly higher in the GA group.
The authors should be commended for their rigorous approach to this study. The number of patients examined lends strength to the study and is substantially higher than in prior studies, thus allowing the examination of infrequent events such as mortality and increasing the precision of the findings. The results also reflect current US practice because the registry collects data on all commercial patients receiving TAVR, leading to highly generalizable results. The time frame under consideration was minimized to mitigate the potential effects of secular bias. A concern in observational studies is confounding, and the authors used rigorous methods, including propensity score analyses using inverse probability of treatment weighting with general estimating equations and a random intercept. Finally, the outcomes under consideration are important.
However, several study design considerations must be kept in mind when evaluating the study results. First, CS is often used by centers with experience in TAVR, and thus high use of CS may be a surrogate for an experienced center with expected excellent outcomes. The authors have mitigated this concern by showing similar results in a subgroup of high-volume centers. Second, a distinct possibility exists that coders in this registry label all patients with an endotracheal tube as GA and all patients without an endotracheal tube as CS. In fact, patients under CS can experience a range of depths of anesthesia-from mere anxiolysis to general anesthesia-that is difficult to quantify in the absence of formal and frequent assessment of arousability. This finding is important because excessive depth of anesthesia has been associated with mortality and delirium in several large studies. 8, 9 The decision to proceed with CS is also not random, and some patients may have received GA because they were high-risk. For instance, the inability to lie flat precludes CS and is often associated with heart failure. The authors have done an admirable job attempting to account for this potential selection bias, but statistical techniques may be insufficient, and the risk of confounding still remains. Finally, the mortality benefit that the authors found is substantial, and thus the lingering notion remains whether patient selection/center experience had a greater role than anesthetic choice.
In light of this study, some pertinent take-home messages for multidisciplinary TAVR teams follow. First, there is an increasing trend toward using CS for transfemoral TAVR procedures in the United States. The rate of CS rose from 11% to 20% within the 15-month studied time frame. Additionally, the number of US sites utilizing CS rose from ≈10% to ≈30%. Current European rates are even higher, reaching close to 98%. Nevertheless, wide variability among US centers still remains, with some large, high-volume academic centers utilizing GA at a rate of 100%. 10 Second, the choice of CS or GA does not appear to impact the procedural success for elective transfemoral TAVR cases. The results of this observational study support the hypothesis that CS may even be superior to GA in eligible patients, with the caveat that limitations inherent in the design of a study such as this make it difficult to ascribe causality.
Third, the conversion rate of 5.9% from CS to GA is not negligible. Urgent induction of GA with intubation may lead to further cardiac or pulmonary instability, which in turn may impact morbidity and mortality. This is an important consideration for optimal staffing models. Many argue that all TAVR cases should be supported by cardiac anesthesiologists, whereas a few centers promote transitioning to a catheterization laboratory model with nurse-administered sedation and without involvement of an anesthesia team member. 6, 11 Both choices have significant economic and staffing implications, which will only compound as TAVR volumes increase. Currently, the high frequency of cardiopulmonary compromise and the need for intubation in a frail population argue for the presence of a cardiac anesthesiologist, although this notion is being reevaluated as procedural success evolves and as patients present with less baseline morbidity.
Finally, the need for a transesophageal echocardiogram (TEE) may dictate anesthetic choice. TEE is highly sensitive in detecting paravalvular leaks, and if TEE is warranted, most providers choose GA for a TAVR. Because paravalvular leaks have been associated with increased late mortality, many argue that a TEE is necessary, and indeed 2 large registry studies support the use of a procedural TEE to decrease the risk of a paravalvular leak. [12] [13] [14] [15] As TAVR transitions into the low-risk patient population, the risk of leak and its associated mortality will have a greater impact. In contrast to highrisk patients, low-risk patients have the option of surgical aortic valve replacement, which carries an extremely low risk of a paravalvular leak. If CS without TEE places these patients at a higher risk of a paravalvular leak, the answer for low-risk patients receiving TAVR may be TAVR with GA, surgical aortic valve replacement, or, in select centers, TAVR with high-dose CS and TEE.
What are the next steps regarding anesthetic management in the burgeoning TAVR field? A nationwide trend in the use of CS seems justified by the results of studies such as this. Although observational studies have limitations, a randomized trial of GA versus CS powered for mortality would require ≈5000 patients and may not be feasible. An alternative approach would be to examine more prevalent or varied outcomes, including hospitalbased outcomes (length of stay, procedural costs/times) or organ outcomes (delirium). However, if CS is truly the wave of the future and anesthetic choice can have such a large effect on outcomes, then future studies need to examine more granular anesthetic variables. In the authors' practice, wide varieties of drugs are used with different pharmacological effects, hemodynamic profiles, and recovery patterns. Additionally, depth of anesthesia may vary considerably and play a role in patient recovery. These factors need to be examined more closely to optimize CS strategies. Nevertheless, in patients receiving TAVR, as in many aspects of medical care, it appears that less may be more.
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